$391 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Buy | BIOGEN INC | $131,842,000 | +9.7% | 413,858 | +7.8% | 33.75% | -9.0% |
| BIVV | New | BIOVERATIV INC | $62,816,000 | – | 1,165,000 | +100.0% | 16.08% | – |
| MDCO | Buy | MEDICINES CO | $52,547,000 | -19.0% | 1,922,000 | +9.7% | 13.45% | -32.8% |
| INVA | Buy | INNOVIVA INC | $51,945,000 | +2.2% | 3,660,705 | +1.7% | 13.30% | -15.3% |
| AGN | New | ALLERGAN PLC | $42,089,000 | – | 257,300 | +100.0% | 10.77% | – |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $24,733,000 | – | 1,650,000 | +100.0% | 6.33% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS INC | $10,649,000 | – | 182,300 | +100.0% | 2.73% | – |
| ACHN | Buy | ACHILLION PHARMACEUTICALS INC | $7,200,000 | -25.0% | 2,500,000 | +17.0% | 1.84% | -37.8% |
| NVLNF | NOVELION THERAPEUTICS INC | $3,198,000 | -55.6% | 1,025,000 | 0.0% | 0.82% | -63.2% | |
| APRI | APRICUS BIOSCIENCES INC | $2,664,000 | +7.6% | 1,447,906 | 0.0% | 0.68% | -10.7% | |
| ABBV | ABBVIE INC | $967,000 | +8.9% | 10,000 | 0.0% | 0.25% | -9.5% | |
| ADXS | Exit | ADVAXIS INC | $0 | – | -339,180 | -100.0% | -0.44% | – |
| Exit | BIOVERATIV INC | $0 | – | -1,165,000 | -100.0% | -20.52% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2018-02-23
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.